initi
vitro
investig
demonstr
type
interferon
ifn
ifna
ifnb
inhibit
replic
sar
coronaviru
sarscov
found
nucleosid
analogu
ribavirin
ineffect
vero
cell
report
ribavirin
shown
inhibit
sarscov
replic
five
differ
cell
type
anim
human
origin
therapeut
achiev
concentr
sinc
clinic
antisarscov
activ
type
interferon
ribavirin
limit
investig
combin
ifnb
ribavirin
determin
viru
yield
indic
highli
synergist
antisarscov
action
combin
suggest
consider
ribavirin
plu
ifnb
treatment
sar
end
new
form
nontyp
pneumonia
sever
acut
respiratori
syndrom
sar
emerg
guangdong
provinc
southern
china
spread
throughout
world
infect
peopl
countri
result
death
http
wwwwhointcsrsar
caus
agent
found
new
member
cororonaviru
famili
sarscoronaviru
sarscov
corticosteroid
antibiot
antivir
agent
empir
use
treatment
sar
rapid
emerg
epidem
permit
conduct
control
studi
document
efficaci
therapi
ribavirin
synthet
guanosin
analogu
broadspectrum
inhibitor
rna
dna
virus
frequent
use
treatment
sar
patient
howev
report
treatment
success
controversi
therapylimit
side
effect
report
sar
patient
first
studi
ribavirin
inhibit
sarscov
replic
vero
african
green
monkey
kidney
cell
newer
experi
demonstr
antisarscov
activ
ribavirin
foetal
rhesu
kidney
cell
concentr
lgml
still
mean
plasma
level
rang
lgml
iv
administr
mg
ribavirin
date
systemat
investig
effect
ribavirin
sarscov
replic
human
cell
line
perform
numer
vitro
studi
effect
interferon
ifn
sarscov
replic
observ
investig
perform
human
colon
carcinoma
cell
vero
cell
demonstr
type
ifn
ifna
ifnb
superior
antisarscov
activ
compar
type
ii
ifnc
although
betaferon
shown
inhibit
sarscov
replic
effect
compar
intron
ifna
subtyp
human
leukocyt
ifna
highli
effect
preliminari
clinic
studi
show
treatment
synthet
recombin
type
ifna
benefici
sar
patient
clinic
evalu
combin
type
ifn
includ
ifnb
ribavirin
patient
chronic
hepat
c
demonstr
superior
combin
either
singl
treatment
result
decreas
pharmacolog
activ
plasma
level
either
drug
test
antisarscov
activ
combin
ribavirin
ifnb
differ
human
anim
cell
vero
cell
grown
mem
supplement
fetal
bovin
serum
fb
contain
iuml
penicillin
lgml
streptomycin
cell
grown
supplement
fb
contain
iuml
penicillin
lgml
streptomycin
human
primari
epitheli
kidney
hpek
cell
prepar
human
renal
tissu
nephrectomi
portion
kidney
carcinoma
free
immunomagnet
isol
describ
grown
medium
fb
sarscov
strain
ffm
strain
courtesi
prof
wilina
lim
govern
viru
unit
hongkong
prepar
infect
vero
cell
cultur
supernat
infect
cultur
collect
day
postinfect
aliquot
store
viru
titr
determin
tissu
cultur
infect
dose
tcid
confluent
cell
microtitr
plate
describ
antivir
assay
confluent
cell
cultur
infect
sarscoronaviru
strain
strain
h
micropl
adsorpt
period
cell
wash
pb
incub
mem
supplement
fb
cytopathogen
effect
cpe
assess
visual
h
infect
experi
viru
yield
reduct
assay
perform
describ
confluent
cell
layer
grown
cm
cell
cultur
flask
infect
sarscov
strain
ffm
h
incub
period
cell
wash
four
time
pb
incub
mem
supplement
fb
h
cultur
supernat
freezethaw
viral
titr
determin
tissu
cultur
infect
dose
tcid
confluent
vero
cell
mictrotitr
plate
inhibitori
effect
express
effect
concentr
compound
requir
inhibit
infecti
viru
titr
ec
ec
ec
control
valu
respect
combin
studi
combin
indic
ci
indic
whether
substanc
act
synergist
addit
antagonist
use
combin
calcul
use
calcusyn
window
calcul
base
method
chou
talalay
ci
lower
indic
synergist
action
ci
higher
indic
antagonist
action
ci
indic
addit
action
cell
inocul
sarscov
strain
moi
maximum
viru
titr
tcid
ml
tcid
ml
tcid
ml
hpek
cell
cell
cell
infect
sarscov
strain
result
infecti
viru
titr
tcid
ml
respect
similar
titr
determin
strain
cpe
detect
h
postinfect
strain
characteris
consider
morpholog
chang
numer
round
enlarg
detach
cell
repres
photograph
shown
fig
cell
shown
ribavirin
inhibit
sarscovrepl
cpe
format
vero
cell
concentr
lgml
howev
ribavirin
inhibit
sarscov
replic
permiss
cell
line
test
tabl
ec
rang
lgml
ec
rang
lg
ml
ec
rang
lgml
found
cell
determin
viru
yield
moi
high
concentr
ribavirin
lgml
complet
suppress
cpe
format
h
pi
cell
line
infect
moi
ribavirin
inhibit
sarscov
strain
similarli
strain
shown
influenc
infecti
dose
antisarscov
activ
ribavirin
investig
cell
infect
differ
moi
measur
viru
titr
ec
valu
lgml
moi
lgml
moi
lgml
moi
show
signific
influenc
infecti
dose
ribavirincaus
sarscov
replic
inhibit
combin
ifnb
ribavirin
test
fix
ratio
iuml
ifnb
lgml
ribavirin
start
iuml
ifnb
lgml
ribavirin
start
concentr
dilut
ratio
combin
synergist
inhibit
sarscovinduc
cpe
cell
repres
photograph
shown
fig
well
product
infecti
viru
tabl
ec
ec
ec
ribavirin
ifnb
combin
infect
human
intestin
cell
line
determin
measur
infecti
viru
titr
exampl
cell
infect
sarscov
strain
moi
ribavirin
concentr
inhibit
viru
product
combin
ifnb
least
lower
compar
cultur
receiv
singl
treatment
ribavirin
inhibitori
concentr
ifnb
decreas
combin
rel
singl
treatment
ifnb
calcul
ci
reveal
highli
synergist
antivir
effect
drug
combin
cell
ci
valu
ec
ec
ec
cell
moi
ci
valu
ec
ec
ec
ribavirin
initi
found
inhibit
sarscov
replic
concentr
lgml
result
obtain
vero
cell
subclon
ribavirin
known
low
antivir
activ
probabl
insuffici
phosphoryl
activ
triphosphoryl
form
recent
studi
show
ribavirin
inhibit
sarscov
replic
cell
concentr
lgml
find
suggest
multipl
cell
cultur
system
use
evalu
activ
antivir
agent
emerg
virus
sarscov
present
studi
effect
ribavirin
sarscov
replic
systemat
investig
panel
sarscov
permiss
cell
line
vero
cell
human
colon
carcinoma
cell
line
pig
kidney
cell
line
alreadi
describ
permiss
sarscov
infect
us
other
african
green
monkey
kidney
cell
line
primari
epitheli
human
kidney
hpek
cell
demonstr
permiss
sarscov
replic
report
hpek
cell
repres
first
normal
diploid
cell
type
human
origin
permiss
sarscov
infect
ribavirin
inhibit
sarscov
replic
newli
test
cell
line
concentr
least
lower
compar
vero
cell
clinic
valu
ribavirin
treatment
sar
patient
regard
sceptic
observ
viral
replic
inhibit
concentr
lgml
ribavirin
reason
therapeut
plasma
level
intraven
dose
mg
ribavirin
may
insuffici
improv
clinic
symptom
concord
randomis
clinic
trial
show
low
dose
mgday
ribavirin
ineffect
hand
recent
publish
studi
report
ribavirin
reduc
viral
load
patient
moreov
studi
suggest
peak
inflammatori
cytokin
level
concur
peak
viral
load
preced
concur
maximum
pulmonari
infiltr
thu
probabl
viral
replic
lead
activ
proinflammatori
cytokin
togeth
factor
contribut
diseas
progress
clinic
find
togeth
observ
antivir
activ
differ
sarscovinfect
cell
line
encourag
test
treatment
strategi
use
ribavirin
combin
antivir
agent
ifn
increas
inhibitori
effect
viru
replic
subsequ
minimis
immunopatholog
damag
type
ifn
shown
inhibit
sarscov
replic
vitro
effect
cell
pretreat
viru
inocul
pilot
clinic
report
demonstr
effect
synthet
recombin
ifna
treatment
sar
patient
overal
find
suggest
high
dose
ifn
exhibit
antisar
effect
mainli
effect
prophylaxi
sar
epidem
reduc
drug
concentr
need
sarscov
inhibit
antisarscov
activ
combin
ribavirin
type
interferon
test
previous
tan
et
al
report
ribavirin
combin
ifnb
demonstr
observ
synergist
effect
wherea
chen
et
al
show
highli
synergist
activ
howev
studi
report
sole
cpe
format
vero
cell
result
demonstr
drug
act
highli
synergist
combin
format
cpe
well
product
infecti
viru
titr
two
human
cell
line
sinc
antivir
drug
ad
viru
adsorpt
result
show
ifnb
combin
ribavirin
may
highli
effect
prophylact
agent
also
treatment
alreadi
infect
sar
patient
conclus
combin
ribavirin
ifnb
inhibit
sarscov
replic
drastic
reduc
concentr
compar
either
singl
treatment
may
enabl
achiev
therapeut
plasma
level
suffici
suppress
sarscov
replic
earli
phase
sar
thu
prevent
subsequ
immunopatholog
damag
moreov
effici
earli
inhibit
viru
replic
may
reduc
viru
shed
consequ
risk
transmiss
